Latest & greatest articles for pantoprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pantoprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pantoprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pantoprazole

1. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial (Full text)

Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial Antiplatelets and anticoagulants are associated with increased upper gastrointestinal bleeding. We evaluated whether proton pump inhibitor therapy could reduce this risk.We performed a 3 × 2 partial factorial double-blind trial of 17,598 participants with stable cardiovascular disease and peripheral artery disease. Participants were randomly (...) assigned to groups given pantoprazole 40 mg daily or placebo, as well as rivaroxaban 2.5 mg twice daily with aspirin 100 mg once daily, rivaroxaban 5 mg twice daily, or aspirin 100 mg alone. The primary outcome was time to first upper gastrointestinal event, defined as a composite of overt bleeding, upper gastrointestinal bleeding from a gastroduodenal lesion or of unknown origin, occult bleeding, symptomatic gastroduodenal ulcer or ≥5 erosions, upper gastrointestinal obstruction, or perforation.There

2019 EvidenceUpdates PubMed abstract

2. Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU. (Full text)

Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU. Prophylaxis for gastrointestinal stress ulceration is frequently given to patients in the intensive care unit (ICU), but its risks and benefits are unclear.In this European, multicenter, parallel-group, blinded trial, we randomly assigned adults who had been admitted to the ICU for an acute condition (i.e., an unplanned admission) and who were at risk for gastrointestinal bleeding to receive 40 mg of intravenous (...) pantoprazole (a proton-pump inhibitor) or placebo daily during the ICU stay. The primary outcome was death by 90 days after randomization.A total of 3298 patients were enrolled; 1645 were randomly assigned to the pantoprazole group and 1653 to the placebo group. Data on the primary outcome were available for 3282 patients (99.5%). At 90 days, 510 patients (31.1%) in the pantoprazole group and 499 (30.4%) in the placebo group had died (relative risk, 1.02; 95% confidence interval [CI], 0.91 to 1.13; P=0.76

2018 NEJM Controlled trial quality: predicted high PubMed abstract

3. Pantoprazole

Pantoprazole Top results for pantoprazole - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for pantoprazole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

4. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease – PAN-STAR (Full text)

Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease – PAN-STAR Proton pump inhibitors therapy success in the treatment of gastroesophageal reflux disease (GERD) is a difficult task because the extent of mucosal damage has no relation with the severity of the symptoms.To establish the efficacy of pantoprazole treatment in patients with erosive reflux disease (ERD) and in those with non-erosive reflux (...) disease (NERD), by assessing symptom relief and quality of life. Treatment duration and adverse events associated with pantoprazole treatment were analysed.This meta-analysis was based on three multicentre, prospective, open-label, phase IV trials conducted in Slovenia, Poland, and the Russian Federation. In total, 252 patients with GERD were included and treated with pantoprazole 40 mg once daily for 4 or 8 weeks, depending on the fulfilment of predefined healing criteria. Symptoms were assessed

2018 PrzeglaÌœd gastroenterologiczny PubMed abstract

5. Withholding Pantoprazole for Stress Ulcer Prophylaxis in Critically Ill Patients: A Pilot Randomized Clinical Trial and Meta-Analysis. (Abstract)

Withholding Pantoprazole for Stress Ulcer Prophylaxis in Critically Ill Patients: A Pilot Randomized Clinical Trial and Meta-Analysis. A decreased frequency of upper gastrointestinal bleeding and a possible association of proton pump inhibitor use with Clostridium difficile and ventilator-associated pneumonia have raised concerns recently. The Reevaluating the Inhibition of Stress Erosions Pilot Trial determined the feasibility of undertaking a larger trial investigating the efficacy and safety (...) of withholding proton pump inhibitors in critically ill patients.In 10 ICUs, we randomized adult ICU patients anticipated to be mechanically ventilated for greater than or equal to 48 hours to receive 40 mg of IV pantoprazole daily or placebo. We excluded patients who had acute or recent gastrointestinal bleed, used dual antiplatelet agents, had a medical condition requiring proton pump inhibitor treatment, or had already received more than one dose of acid suppression daily. Patients, families, clinicians

2017 Critical Care Medicine Controlled trial quality: uncertain

6. Continuous versus Intermittent Intravenous Pantoprazole for Acute Gastrointestinal Bleeding

Continuous versus Intermittent Intravenous Pantoprazole for Acute Gastrointestinal Bleeding Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid (...) Intravenous Pantoprazole for Acute Gastrointestinal Bleeding: A Review of the Clinical Effectiveness and Guidelines DATE: 01 May 2015 CONTEXT AND POLICY ISSUES The gastrointestinal (GI) tract stretches from the mouth to the anus and gastrointestinal bleeding describes any bleeding that starts in the GI tract. Acute GI bleeding refers to the passage of a clinically significant amount of blood (i.e., the passage of more than a scant amount of blood) 1 Acute bleeding in the upper part of the GI tract often

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Controloc Control - pantoprazole

Controloc Control - pantoprazole European Medicines Agency Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: mail@emea.europa.eu http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged. London, 8 May 2009 Doc.Ref.: EMEA/374215/2009 ASSESSMENT REPORT FOR CONTROLOC Control International Nonproprietary Name: pantoprazole Procedure (...) of heartburn is universal and that it is in patients’ interest across the community to allow access to a harmonised non- prescription pantoprazole product. In addition, it would give Community-wide access and consumer protection, based on harmonised labelling and avoid diverted markets. The legal basis for this application refers to Article 10(3) of Directive 2001/83/EC, as amended – hybrid application. The chosen reference product is: Reference medicinal product which is or has been authorised

2009 European Medicines Agency - EPARs

8. Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding

Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding Wang J, Yang K, Ma B, Tian J, Liu Y, Bai Z, Jiang L, Sun S, Li J, Liu R, Hao X, He X CRD summary The authors concluded that intravenous pantoprazole (...) administered after endoscopic treatment reduces ulcer re-bleeding, surgical intervention, and length of hospital stay, but not mortality nor blood transfusions. This was a generally well-conducted review and the findings for the overall analyses are likely to be reliable. Authors' objectives To evaluate the effectiveness of intravenous pantoprazole as an additional treatment following successful endoscopic haemostasis of peptic ulcer bleeding. Searching The Cochrane Central Register of Controlled Trials

2009 DARE.

9. Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding. (Full text)

Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding. Several studies have suggested that proton pump inhibitors are efficacious in preventing rebleeding when administered immediately after endoscopic treatments. However, there are limited clinical outcome data on the use of intravenous pantoprazole.To evaluate the efficacy of intravenous pantoprazole after successful endoscopic treatment for peptic ulcer bleeding using evidence (...) from randomized controlled trials (RCTs).The Cochrane Library, MEDLINE, EMBASE and several Chinese databases up to July 2008 were searched. RCTs that compared the relative effectiveness of intravenous pantoprazole with placebo, H2 receptor antagonist or other agents for patients with peptic ulcer bleeding who were pretreated with successful endoscopic therapies were retrieved.Five RCTs comprising a total of 821 participants were included in the final meta-analysis. Overall, there were significant

2009 Canadian journal of gastroenterology = Journal canadien de gastroenterologie PubMed abstract

10. Pantoprazole magnesium

Pantoprazole magnesium Common Drug Review CEDAC Meeting – June 21, 2006 Page 1 of 2 Notice of CEDAC Final Recommendation – July 20, 2006 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION PANTOPRAZOLE MAGNESIUM (Pantoloc M™ – Altana Pharma Inc.) Description: Pantoprazole magnesium is a new salt form of pantoprazole, a widely used proton pump inhibitor (PPI). It is approved for use in conditions where a reduction of gastric acid is required, such as the following: duodenal ulcer, gastric (...) ulcer, reflux esophagitis and symptomatic gastro- esophageal reflux disease (such as, acid regurgitation and heartburn). Additionally, pantoprazole, in combination with clarithromycin and either amoxicillin or metronidazole, is approved for use in the treatment of patients with an active duodenal ulcer who are H. pylori positive. Dosage Forms: 40 mg enteric coated tablet Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that pantoprazole magnesium be listed in a similar

2006 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

11. Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions

Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions Kaplan G G, Bates D, McDonald D, Panaccione R, Romagnuolo J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of an intravenous proton pump inhibitor (IV PPI), pantoprazole, in patients with upper gastrointestinal bleeding (UGIB) or patients receiving nil by mouth (NPO). In connection to this, the study examined the use of a multidisciplinary intervention to reduce inappropriate use of IV PPI. This intervention had four

2005 NHS Economic Evaluation Database.

12. Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. (Abstract)

Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. To perform a systematic review on the efficacy of pantoprazole based therapies in Helicobacter pylori eradication, and to conduct a meta-analysis comparing the efficacy of pantoprazole and other proton pump inhibitors (PPIs) when co-prescribed with antibiotics.Studies evaluating pantoprazole combined with antibiotics were considered. Only randomized clinical trials comparing pantoprazole (...) and other PPIs when co-prescribed with antibiotics, and differing only in the PPI (pantoprazole vs other), were eligible for inclusion in the meta-analysis. Bibliographical searches in several electronic databases, and manual search of abstracts from congresses, were conducted. The percentage (weighted mean) of patients with eradication success was calculated. Meta-analysis was performed combining the odds ratios (ORs) of the individual studies in a global OR.The mean eradication rate with pantoprazole

2004 European journal of gastroenterology & hepatology

13. Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. (Abstract)

Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. Effective symptom control is a primary concern of most heartburn suffers.To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis.Data from two randomized, double-blind studies were pooled. Patients received pantoprazole 10, 20 or 40 mg, or placebo daily (study 1, n = 603), or pantoprazole 20 (...) or 40 mg daily or 150-mg nizatidine b.d. (study 2, n = 243) for either 4 or 8 weeks. Endoscopy was performed at baseline, week 4 and week 8. Persistent absence of symptoms was defined as the first day that no symptoms were reported by the patient on that day or any subsequent study day.A significantly higher percentage (P < 0.05) of pantoprazole patients reported elimination of all symptoms by week 8. Daytime heartburn, night-time heartburn and regurgitation were significantly better controlled

2004 Alimentary pharmacology & therapeutics

14. A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands. (Abstract)

A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands. The focus of treatment of patients with peptic ulcer or gastroesuphageal reflux disease has changed during the last 15 years, with a shift from histamine2-receptor antagonists to proton-pump inhibitors (PPIs). From 1993 to 2000, expenditures for omeprazole (90% of total market share of PPIs) increased in The Netherlands (...) from 68 million euros to 230 million euros. In 1999, expenditures for pantoprazole accounted for the majority of the rest of the market share for PPIs.The objective of this study was to compare the efficacy and costs of treatment with pantoprazole and omeprazole in The Netherlands.First, we reviewed clinical studies that compared the efficacy of different dosages of omeprazole and pantoprazole. Second, we analyzed data from a nationwide database of drug prescriptions to determine the dosages used

2003 Clinical therapeutics

15. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing (...) and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Caro J J, Salas M, Ward A Authors' objectives To estimate the healing and relapse rates in the acute and maintenance treatment of gastroesophageal reflux disease (GERD) with the newer proton-pump inhibitors (PPIs) lansoprazole, rabeprazole and pantoprazole, compared

2001 DARE.

16. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. (Abstract)

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. The older proton pump inhibitor (PPI) omeprazole and the newer PPIs lansoprazole, rabeprazole, and pantoprazole are approved for the acute and maintenance treatment of gastroesophageal reflux disease (GERD).On the basis of the results of randomized (...) of acute therapy was healing rate, and the primary outcome for studies of maintenance therapy was relapse rate.Fifty-three studies were identified, of which 38 involved acute therapy (12 excluded) and 15 maintenance therapy. None of the studies of pantoprazole met the inclusion criteria for maintenance therapy. The 8-week overall healing rate ratios in the comparison of newer PPIs with omeprazole 20 mg/d were as follows: lansoprazole 30 mg/d, 1.02 (95% CI, 0.98-1.06): rabeprazole 20 mg/d, 0.93 (95% CI

2001 Clinical therapeutics

17. Pantoprazole

Pantoprazole Pantoprazole Pantoprazole Poole P Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Poole P. Pantoprazole. University HealthSystem Consortium (UHC). Drug Monograph. 2000 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new and emerging pharmaceuticals. Monographs are written by drug

2000 Health Technology Assessment (HTA) Database.